Interventional cardiologists in Detroit developed the new technique with a specific patient in mind. One specialist described it as an "exciting breakthrough."

The new drug, asundexian, is currently the subject of two multicenter Phase III studies—the OCEANIC-AF trial and OCEANIC-STROKE trial—focused on its safety and efficacy.

“These and other data support that young adults do as well as a more traditional patient population when looking at arrhythmia-free survival,” researchers wrote.

“I was ready to make out my will, so this came along just at the right time,” the 76-year-old patient said. 

Cardiology is linked to the second largest group of FDA-cleared clinical AI algorithms, and the number is still growing. 

A new-look TAVR valve was tested on patients for the first time, leading researchers to say its use appears to be "feasible and safe." More research, of course, is still required. 

New data suggest that the burden of atherosclerosis on imaging might not be as indicative of major cardiovascular events as a person’s age and sex. 

Heart Rhythm 2023, the society's 44th annual meeting, is scheduled for May 19-21.